ContraFect (CFRX) Upgraded to “Buy” by ValuEngine

Share on StockTwits

ValuEngine upgraded shares of ContraFect (NASDAQ:CFRX) from a hold rating to a buy rating in a report published on Tuesday.

Separately, LADENBURG THALM/SH SH started coverage on ContraFect in a report on Tuesday, July 10th. They set a buy rating for the company.

NASDAQ CFRX opened at $2.39 on Tuesday. ContraFect has a twelve month low of $0.85 and a twelve month high of $2.93.

ContraFect (NASDAQ:CFRX) last released its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.17). As a group, sell-side analysts predict that ContraFect will post -0.37 EPS for the current fiscal year.

Institutional investors have recently made changes to their positions in the business. Acadian Asset Management LLC acquired a new position in shares of ContraFect during the second quarter valued at approximately $111,000. JPMorgan Chase & Co. acquired a new position in shares of ContraFect during the first quarter valued at approximately $131,000. Trellus Management Company LLC raised its holdings in shares of ContraFect by 88.8% during the third quarter. Trellus Management Company LLC now owns 83,955 shares of the biotechnology company’s stock valued at $174,000 after acquiring an additional 39,492 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of ContraFect by 40.6% during the second quarter. Renaissance Technologies LLC now owns 200,500 shares of the biotechnology company’s stock valued at $443,000 after acquiring an additional 57,900 shares during the last quarter. 54.73% of the stock is owned by institutional investors and hedge funds.

About ContraFect

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.

Featured Article: What does cost of debt say about a company’s financial health?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply